Chiesi, Protalix's Fabry disease treatment is approved as Elfabrio joins Fabrazyme, Galafold
The FDA has greenlit an enzyme replacement therapy for adults with a rare, inherited disease in which abnormal deposits of fatty substances build up and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
